

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康豐生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

INSIDE INFORMATION ANNOUNCEMENT

ISSUANCE OF FILING NOTICE BY CSRC FOR H SHARE FULL CIRCULATION APPLICATION OF COMPANY

This announcement is made by Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company has recently submitted a filing to the China Securities Regulatory Commission (中國證券監督管理委員會) (the “**CSRC**”) regarding the implementation of the full circulation of H shares of the Company (the “**CSRC Filing**”). Under the CSRC Filing, the Company has made an application to the CSRC on behalf of certain shareholders of the Company for the conversion of a total of 29,341,981 unlisted shares of the Company held by such shareholders into H shares of the Company and the listing thereof on the Stock Exchange (the “**Conversion and Listing**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on March 7, 2024, the CSRC issued a filing notice to the Company (the “**Filing Notice**”) in respect of the Conversion and Listing. According to the Filing Notice, the CSRC Filing in relation to the Conversion and Listing has been completed, and if the Company wishes to continue the Conversion and Listing after 12 months from the date of the issuance of the Filing Notice, an updated filing to the CSRC would be required.

As at the date of this announcement, the details of the implementation plan of the Conversion and Listing have not been finalized. The Company will make further announcement(s) on the progress of the Conversion and Listing in accordance with the requirements under the Listing Rules and/or the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance.

The Conversion and Listing are subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, March 11, 2024

As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.